Ana Redondo of Guys and St Thomas’s Hospital gives a talk on the Ross PEARS procedure at the EACTS (European Association for Cardio-Thoracic Surgery) Aortic Forum in Bologna, which ran 15-16 November 2021.
The forum featured live surgical cases, interactive lectures, live-in-a-box videos and abstract presentations. You can see the full programme of the event on the EACTS website.
Tal Golesworthy gave an update on PEARS at the Marfan Trust’s Marfan Information Day 2021, which was held virtually on 9 October 2021. The event was a day devoted to discussion of all things Marfan syndrome, from matters of the heart, eyes, and skeleton, to advice on psychological support, pregnancy and more.
In the last week, two peer-reviewed clinical papers on ExoVasc® have been published discussing the observed desired clinical outcomes of the PEARS procedure.
The first ‘Personalised external aortic root support for elective treatment of aortic root dilation in 200 patients’, by Lucas Van Hoof et al, published in Heart, Journal of the British Cardiovascular Society, discusses the results of a clinical study performed on the first 200 consecutive ExoVasc patients following implantation at 23 different centres between 2004 and 2019. Based on 596 postoperative patient years, it concludes that PEARS has a low operative mortality and that aortic dissection has not been observed to date in the part of the aorta restrained by the ExoVasc® PEARS implant.
The second ‘Personalized External Aortic Root Support (PEARS) for Aortic Root Aneurysm’, by Louise A Kenny et al, published in Operative Techniques in Thoracic and Cardiovascular Surgery: A Comparative Atlas, describes the preoperative planning and surgical technique for the ExoVasc® Personalised Aortic Root Support with detailed illustrations. It also concludes that following implantation in 384 patients, the author is not aware of any patient with aortic dissection or rupture following PEARS.
Exstent Limited has completed its relocation to new premises on Tewkesbury Business Park. The larger facility is equipped with a more spacious cleanroom for the production of ExoVasc® Personalised External Aortic Root Support implants, and accommodates the enlarged team as the company meets the growing demand for this innovative device.
We are pleased to announce the appointment of Victoria Sharpe as the new Managing Director of Exstent Limited. Victoria is a Chartered Engineer with a wealth of experience in the medical device industry and will lead the company through the next phase of its growth.